Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Short-term Investments (2017 - 2025)

Historic Short-term Investments for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Q3 2025 value amounting to $23000.0.

  • Lineage Cell Therapeutics' Short-term Investments fell 9953.64% to $23000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $23000.0, marking a year-over-year decrease of 9953.64%. This contributed to the annual value of $2.0 million for FY2024, which is 393200.0% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Short-term Investments stood at $23000.0 for Q3 2025, which was down 9953.64% from $17000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Short-term Investments registered a high of $46.5 million during Q4 2022, and its lowest value of $17000.0 during Q2 2025.
  • Its 5-year average for Short-term Investments is $9.5 million, with a median of $4.3 million in 2021.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Short-term Investments tumbled by 9989.25% in 2023 and then soared by 393200.0% in 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' Short-term Investments (Quarter) stood at $2.6 million in 2021, then soared by 1678.29% to $46.5 million in 2022, then plummeted by 99.89% to $50000.0 in 2023, then surged by 3932.0% to $2.0 million in 2024, then tumbled by 98.86% to $23000.0 in 2025.
  • Its Short-term Investments stands at $23000.0 for Q3 2025, versus $17000.0 for Q2 2025 and $19000.0 for Q1 2025.